NR1D2 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-07-21 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
=== Therapy studies === Due to the rarity of the disease, many important questions about adrenocortical carcinoma remain unanswered. Therefore, as many patients as possible should be treated in registry studies or therapy studies.
Eannatum (Sumerian: 𒂍𒀭𒈾𒁺 É.AN.NA-tum2; fl. c. 2450 BC) was a Sumerian Ensi (ruler or king) of Lagash. He established one of the first verifiable empires in history, subduing Elam and destroying the city of Susa, and extending his domain over the rest of Sumer and Akkad. One inscription found on a boulder states that Eannatum was his Sumerian name, while his "Tidnu" (Amorite) name was Lumma.
== Chemistry == Selenocysteine is the Se-analogue of cysteine. It is rarely encountered outside of living tissue (nor is it available commercially) because of its high susceptiblility to air-oxidation. More common is the oxidized derivative selenocystine, which has an Se-Se bond. Both selenocysteine and selenocystine are white solids. The Se-H group is more acidic (pKa = 5.43) than the thiol group; thus, it is deprotonated at physiological pH.
Sources: en.wikipedia.org
== History == Jasons Market Place started its business in Singapore in 1975. It was introduced in Taiwan in 2003. In 2007, it opened in Hong Kong's Jardine's Lookout under the name "Market Place by Jasons". In 2012, Jasons Food Hall began operations in the Bangsar Shopping Centre, an upmarket shopping mall in the township of Bangsar, Malaysia, as a replacement for a Cold Storage store. Jasons Market Place in Taiwan was sold to Carrefour in 2020 and rebranded as Mia C'bon from 2022.
In spite of this complex mixture of religious traditions, generally, the prevailing artistic style at any time and place has been shared by the major religious groups, and sculptors probably usually served all communities. Gupta art, at its peak c. 300 CE – c. 500 CE, is often regarded as a classical period whose influence lingered for many centuries after; it saw a new dominance of Hindu sculpture, as at the Elephanta Caves. Across the north, this became rather stiff and formulaic after c. 800 CE, though rich with finely carved detail in the surrounds of statues. But in the South, under the Pallava and Chola dynasties, sculpture in both stone and bronze had a sustained period of great achievement; the large bronzes with Shiva as Nataraja have become an iconic symbol of India. Ancient paintings have only survived at a few sites, of which the crowded scenes of court life in the Ajanta Caves are some of the most important. Painted manuscripts of religious texts survive from Eastern India from 10th century onwards, most of the earliest being Buddhist and later Jain. These significantly influenced later artistic styles. The Persian-derived Deccan painting, starting just before the Mughal miniature, between them give the first large body of secular painting, with an emphasis on portraits, and the recording of princely pleasures and wars. The style spread to Hindu courts, especially among the Rajputs, and developed a variety of styles, with the smaller courts often the most innovative, with figures such as Nihâl Chand and Nainsukh.
== History == OpenELIS has early documented implementations in clinical and reference laboratories in Haiti and Côte d'Ivoire. In Côte d'Ivoire, the system has been in routine use since 2009, developed jointly with the country's Ministry of Health and the University of Washington's International Training and Education Center for Health, with funding from the President's Emergency Plan for AIDS Relief (PEPFAR); by 2021 it had been installed in more than 100 laboratories covering HIV, tuberculosis, food and drug safety, and routine testing data. The system was subsequently implemented in other countries, including Vietnam.
Sources: en.wikipedia.org
Similarly, the compressive strength that describes the yield stress before plastic deformation under compression in graphene aerogels follows a power-law distribution: σy/Es = (ρ/ρs)n, where σy is the compressive strength, ρ is the density of the graphene aerogel, Es is the modulus of graphene, ρs is the density of graphene, and n is the power-law scaling factor that describes the system different from the exponent observed in the modulus. The power-law dependence observed agrees with trends between density and modulus and compressive strength observed in experimental studies on graphene aerogels. The macroscopic geometric structure of the aerogel has been shown both computationally and experimentally to affect mechanical properties observed. 3D-printed periodic hexagonal graphene aerogel structures exhibited an order-of-magnitude larger modulus compared to bulk graphene aerogels of the same density when the force is applied along the vertical axis. The dependence of stiffness on structure is commonly observed in other cellular structures.
The actual preparation of the brew takes several hours, often taking place over the course of more than one day. After adding the plant material, each separately at this stage, to a large pot of water, it is boiled until the water is reduced by half in volume. The individual brews are then combined and brewed until reduced significantly, producing the form taken by participants in ayahuasca ceremonies.
The Bristol Brabazon was a large trans-Atlantic airliner built in the late 1940s, based on developments in heavy bombers during World War II, but it received no sales orders and never went into production. Concorde, the first supersonic airliner was built in the 1960s, first flying in 1969. The aircraft never achieved commercial success, but its development did lay the foundation for the successful Airbus series of airliners, parts of which are produced at Filton in the 21st century. In the 1980s the financial services sector became a major employer in the city and surrounding areas, such as the business parks on the northern fringe of what was now referred to as Greater Bristol or the Bristol Urban Area comprising the city, Easton-in-Gordano, Frampton Cottrell and Winterbourne, Kingswood, Mangotsfield and Stoke Gifford. High technology companies such as IBM, Hewlett Packard, Toshiba, and Orange, along with creative and media enterprises become significant local employers as traditional manufacturing industries declined. Like much of British post-war planning, regeneration of Bristol city centre was characterised by large, cheap tower blocks, brutalist architecture and expansion of roads. Since the 1990s this trend has been reversed, with the closure of some main roads and the regeneration of the Broadmead shopping centre. In 2006 one of the city centre's tallest post-war blocks was torn down. Social housing tower blocks have also been demolished to be replaced by low rise homes.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.